MolecularMD prides itself on providing our pharmaceutical clients with industry leading validation protocols and documentation to help support the adoption of our pharmacogenomic tests in late stage clinical trials.
Critical to timely and thorough assay validation is access to sample tissues that harbor the range of mutations and target expression levels. MolecularMD maintains relationships with leading clinical research institutes that can provide a broad range of malignant tissues and blood samples necessary to validate typical or atypical molecular markers. Our collaborative relationship with the Knight Cancer Institute at Oregon Health & Science University also helps to provide samples that have been pre-screened for certain genomic mutations, helping to greatly accelerate the validation process.
MolecularMD employs a range of technologies and chemistry protocols to perform extensive cross validation. MolecularMD is not committed to any particular platform or chemistry and will base the validation on the methodology that best meets all of the criteria of the clinical study such as cost, sensitivity, sample procurement, and turn-around time.